Rapid Dose Therapeutics Submits QuickStrip(TM) Nicotine Product for Health Canada Approval
Rapid Dose Therapeutics (CSE: DOSE) has submitted its QuickStrip™ Nicotine products for Health Canada approval in multiple dosage formats (1mg, 2mg, 3mg, and 4mg). The product is an innovative oral thin film technology that delivers nicotine through the oral mucosa as a safer alternative to smoking.
The company is currently conducting a pharmacokinetic (PK) clinical trial comparing QuickStrip™ Nicotine to traditional cigarettes. RDT has collaborated with a leading global cigarette manufacturer over the past 30 months and filed two PCT patent applications with partner Aavishkar.
The Canadian nicotine pouches market, valued at $112.2 million in 2024, is projected to grow at 4.7% annually through 2030. This submission follows a previous 2019 application that was interrupted by COVID-19.
Rapid Dose Therapeutics (CSE: DOSE) ha presentato per l'approvazione di Health Canada i suoi prodotti QuickStrip™ Nicotina in diversi formati di dosaggio (1mg, 2mg, 3mg e 4mg). Il prodotto utilizza una tecnologia innovativa di film orale sottile che somministra nicotina attraverso la mucosa orale, rappresentando un'alternativa più sicura al fumo.
L'azienda sta attualmente conducendo uno studio clinico farmacocinetico (PK) per confrontare QuickStrip™ Nicotina con le sigarette tradizionali. RDT ha collaborato con un importante produttore globale di sigarette negli ultimi 30 mesi e ha depositato due domande di brevetto PCT insieme al partner Aavishkar.
Il mercato canadese delle buste di nicotina, valutato a 112,2 milioni di dollari nel 2024, è previsto in crescita del 4,7% annuo fino al 2030. Questa richiesta segue una precedente domanda del 2019, interrotta a causa del COVID-19.
Rapid Dose Therapeutics (CSE: DOSE) ha presentado para la aprobación de Health Canada sus productos QuickStrip™ Nicotina en varios formatos de dosis (1mg, 2mg, 3mg y 4mg). El producto es una innovadora tecnología de película oral delgada que administra nicotina a través de la mucosa oral como una alternativa más segura al fumar.
La compañía está realizando actualmente un ensayo clínico farmacocinético (PK) que compara QuickStrip™ Nicotina con los cigarrillos tradicionales. RDT ha colaborado con un fabricante global líder de cigarrillos durante los últimos 30 meses y ha presentado dos solicitudes de patente PCT junto con su socio Aavishkar.
El mercado canadiense de bolsas de nicotina, valorado en 112,2 millones de dólares en 2024, se proyecta que crezca a una tasa anual del 4,7% hasta 2030. Esta presentación sigue a una solicitud previa de 2019 que fue interrumpida por el COVID-19.
Rapid Dose Therapeutics (CSE: DOSE)는 다양한 용량(1mg, 2mg, 3mg, 4mg)의 QuickStrip™ 니코틴 제품을 Health Canada 승인을 위해 제출했습니다. 이 제품은 구강 점막을 통해 니코틴을 전달하는 혁신적인 경구용 얇은 필름 기술로, 흡연에 대한 더 안전한 대안입니다.
회사는 현재 QuickStrip™ 니코틴과 전통적인 담배를 비교하는 약동학(PK) 임상시험을 진행 중입니다. RDT는 지난 30개월간 글로벌 선도 담배 제조업체와 협력했으며, 파트너 Aavishkar와 함께 두 건의 PCT 특허 출원을 완료했습니다.
2024년 기준 1억 1,220만 달러 규모2030년까지 연평균 4.7% 성장할 것으로 예상됩니다. 이번 제출은 COVID-19로 중단된 2019년 이전 신청에 이은 것입니다.
Rapid Dose Therapeutics (CSE : DOSE) a soumis ses produits QuickStrip™ Nicotine pour approbation auprès de Santé Canada dans plusieurs formats de dosage (1mg, 2mg, 3mg et 4mg). Ce produit est une technologie innovante de film oral fin qui délivre la nicotine à travers la muqueuse buccale, offrant une alternative plus sûre au tabagisme.
L'entreprise mène actuellement un essai clinique pharmacocinétique (PK) comparant QuickStrip™ Nicotine aux cigarettes traditionnelles. RDT a collaboré avec un fabricant mondial de cigarettes de premier plan au cours des 30 derniers mois et a déposé deux demandes de brevet PCT avec le partenaire Aavishkar.
Le marché canadien des sachets de nicotine, évalué à 112,2 millions de dollars en 2024, devrait croître de 4,7 % par an jusqu'en 2030. Cette soumission fait suite à une demande précédente en 2019 interrompue par la COVID-19.
Rapid Dose Therapeutics (CSE: DOSE) hat seine QuickStrip™ Nikotin-Produkte in mehreren Dosierungsformen (1mg, 2mg, 3mg und 4mg) zur Zulassung bei Health Canada eingereicht. Das Produkt ist eine innovative orale Dünnfilmtechnologie, die Nikotin über die Mundschleimhaut als sicherere Alternative zum Rauchen abgibt.
Das Unternehmen führt derzeit eine pharmakokinetische (PK) klinische Studie durch, in der QuickStrip™ Nikotin mit herkömmlichen Zigaretten verglichen wird. RDT hat in den letzten 30 Monaten mit einem führenden globalen Zigarettenhersteller zusammengearbeitet und zusammen mit dem Partner Aavishkar zwei PCT-Patentanmeldungen eingereicht.
Der kanadische Markt für Nikotintaschen, der im Jahr 2024 auf 112,2 Millionen US-Dollar geschätzt wird, soll bis 2030 mit 4,7 % jährlich wachsen. Diese Einreichung folgt auf einen früheren Antrag aus dem Jahr 2019, der durch COVID-19 unterbrochen wurde.
- Development of innovative nicotine delivery system targeting large market opportunity
- Strategic partnership with leading global cigarette manufacturer
- Two international patent applications filed for proprietary technology
- Multiple dosage formats (1-4mg) allowing personalized usage
- Targeting growing nicotine pouches market valued at $112.2M with 4.7% annual growth
- Previous 2019 Health Canada application was unsuccessful due to COVID-19
- Product still pending regulatory approval and clinical trial results
- Faces competition in established nicotine replacement therapy market
Innovative Oral Nicotine Delivery Technology Targets Safer Alternative for Smokers
Burlington, Ontario--(Newsfile Corp. - August 4, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company focused on innovative drug delivery technologies, is pleased to announce the submission of a product application to Health Canada for approval of its QuickStrip™ Nicotine products in 1 mg, 2 mg, 3 mg, and 4 mg formats. This regulatory milestone marks a significant step toward the commercialization of RDT's proprietary oral nicotine delivery system, which has been developed as a safer alternative to smoking.
QuickStrip™ is a fast-dissolving oral thin film that delivers active ingredients directly through the oral mucosa. RDT's NicStrip™ product line leverages this platform to provide nicotine in a controlled, smoke-free format, aimed at helping smokers reduce or quit smoking altogether. The nicotine products are currently undergoing a pharmacokinetic (PK) clinical trial, comparing QuickStrip™ Nicotine to traditional combustible cigarettes in order to evaluate absorption and efficacy.
"We believe this submission represents a critical advancement in our mission to support harm reduction for smokers," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "With millions of Canadians seeking safer nicotine alternatives, QuickStrip™ offers a convenient, discreet, and non-combustible option. Our goal is to empower individuals with effective tools to reduce the health risks associated with smoking."
Over the past 30 months, RDT has worked closely with a leading global cigarette manufacturer to refine the QuickStrip™ Nicotine product in preparation for launch. This strategic partnership has enabled extensive R&D toward product optimization, laying the groundwork for regulatory submission and commercialization. RDT and its production partner Aavishkar have filed two international patent applications under the Patent Cooperation Treaty (PCT), covering advancements in nicotine delivery, film formulation, and controlled-release technology.
The current PK study is being conducted under Good Clinical Practice (GCP) guidelines and is designed to gather detailed data on the bioavailability of nicotine delivered via the QuickStrip™ platform compared to inhaled nicotine from cigarettes. Results will support product claims and regulatory positioning and are a key component of the Health Canada submission.
"Our QuickStrip™ delivery system is designed to mimic the nicotine absorption curve of a cigarette without the harmful by products of combustion," said Jason Lewis, Senior Vice President of RDT. "It provides rapid onset, consistent dosing, and eliminates second-hand smoke-critical attributes for any successful smoking cessation or harm reduction strategy."
The product is intended to be used by adult smokers who are seeking to reduce or quit tobacco use. With the inclusion of multiple dose strengths (1 mg to 4 mg), QuickStrip™ Nicotine allows users to personalize their nicotine intake and taper use over time, supporting individualized usage plans.
Upon regulatory approval, RDT plans to launch the product across Canada and to expand distribution through its commercial partnerships, including potential licensing in other global markets.
"Today's announcement underscores our commitment to innovation and public health," added Lewis. "We're not just developing a product-we're contributing to a movement toward safer alternatives for nicotine users.
Background & Market Opportunity
Rapid Dose Therapeutics previously submitted a nicotine product application to Health Canada in 2019. However, due to the COVID-19 pandemic, the regulatory process could not be completed at that time.
The Canadian nicotine pouches market was valued at USD 112.2 million in 2024, with projected annual growth of
This initiative aligns with the Government of Canada's Tobacco Strategy (CTS), which aims to reduce tobacco use to less than
For more information, please contact:
RDT Investor Contact:
Mark Upsdell, CEO
Investorrelations@rapid-dose.com
416-477-1052
About Rapid Dose Therapeutics
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through its proprietary QuickStrip™ technology-a fast-dissolving, thin oral film that offers precise dosing and rapid onset. RDT offers a full-service, turn-key solution for product development, manufacturing, and commercialization of novel oral drug delivery products in both the consumer and pharmaceutical sectors.
Forward-Looking Information
This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking statements include statements related to the approval, efficacy, and commercialization of RDT's QuickStrip™ Nicotine product. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. RDT undertakes no obligation to update or revise these statements, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261147
FAQ
What is Rapid Dose Therapeutics' QuickStrip Nicotine product and how does it work?
When did RDTCF submit its QuickStrip Nicotine product to Health Canada?
What is the market potential for RDTCF's nicotine product in Canada?
What clinical trials is RDTCF conducting for QuickStrip Nicotine?
Who is RDTCF partnering with for the QuickStrip Nicotine development?
